Centro Cardiologico Monzino, IRCCS, Milan, Italy.
Dept of Cardiology, University of Foggia, Foggia, Italy.
Eur Respir Rev. 2018 May 2;27(148). doi: 10.1183/16000617.0134-2017. Print 2018 Jun 30.
Despite recent advances in the therapeutic management of patients affected by pulmonary arterial hypertension (PAH), survival remains poor. Prompt identification of the disease, especially in subjects at increased risk of developing PAH, and prognostic stratification of patients are a necessary target of clinical practice but remain challenging. Cardiopulmonary exercise test (CPET) parameters, particularly peak oxygen uptake, end-tidal carbon dioxide tension and the minute ventilation/carbon dioxide production relationship, emerged as new prognostic tools for PAH patients. Moreover, CPET provides a comprehensive pathophysiological evaluation of patients' exercise limitation and dyspnoea, which are the main and early symptoms of the disease. This review focuses on the role of CPET in the management of PAH patients, reporting guideline recommendations for CPET and discussing the pathophysiology of exercise limitation and the most recent use of CPET in the diagnosis, prognosis and therapeutic targeting of PAH.
尽管最近在治疗肺动脉高压 (PAH) 患者方面取得了进展,但患者的生存率仍然很低。及时识别疾病,特别是在有发生 PAH 风险的患者中,以及对患者进行预后分层,是临床实践的必要目标,但仍然具有挑战性。心肺运动试验 (CPET) 参数,特别是峰值摄氧量、呼气末二氧化碳分压和分钟通气量/二氧化碳产量关系,已成为 PAH 患者新的预后工具。此外,CPET 为患者运动受限和呼吸困难(该疾病的主要和早期症状)提供了全面的病理生理学评估。这篇综述重点介绍了 CPET 在 PAH 患者管理中的作用,报告了 CPET 的指南建议,并讨论了运动受限的病理生理学以及 CPET 在 PAH 的诊断、预后和治疗目标中的最新应用。